MAPS Trial: Matrix And Platinum Science A Prospective, Randomized, Multicenter Trial Investigating Matrix2 TM and GDC® Coils For the Treatment of Intracranial Saccular Aneurysms May 5, 2022 By Jesse Bufkin
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study May 5, 2022 By Jesse Bufkin
This AAA account is being set up solely for Pharmacy’s purpose of capturing charges that are not being reimbursed by the Southwest Oncology Group (SWOG) and the lead PI is Fred Appelbaum. The charges to the account will be for dispensing fees and adminis May 5, 2022 By Jesse Bufkin
This RRR account was setup solely for Pharmacy’s purpose of capturing charges that are not being reimbursed by the American College of Surgeons Oncology Group (ACOSOG) and the lead PI is Gary Mann. The Charges to the account will be for dispensing fees an May 5, 2022 By Jesse Bufkin
Evaluation of the GORE TAG® Thoracic Endoprosthesis — 45 mm for the Primary Treatment of Aneurysms of the Descending Thoracic Aorta May 5, 2022 By Jesse Bufkin
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability,and Efficacy of Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 May 5, 2022 By Jesse Bufkin
Molecular correlates of sensitivity and resistance to therapy in prostate cancer May 5, 2022 By Jesse Bufkin
A Phase II Study of Sorafenib (Nexavar) Prior to Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer May 5, 2022 By Jesse Bufkin
